Equities

Zhengye Biotechnology Holding Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ZYBT:NAQ

Zhengye Biotechnology Holding Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.8090
  • Today's Change0.039 / 5.06%
  • Shares traded14.79k
  • 1 Year change-81.14%
  • Beta--
Data delayed at least 15 minutes, as of Mar 04 2026 19:36 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zhengye Biotechnology Holding Ltd is a company mainly engaged in the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. The Company markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The Company owns about 44 veterinary vaccines in its product portfolio, which cover veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The Company also engages in vaccines for treating livestock. The Company mainly conducts its business in the domestic market. The Company mainly conducts its business in the domestic and overseas market.

  • Revenue in USD (TTM)22.28m
  • Net income in USD-2.81m
  • Incorporated2023
  • Employees277.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TherapeuticsMD Inc2.80m73.00k25.70m1.00355.770.936255.869.190.00620.02610.24192.370.0715--0.80022,796,000.000.1867-42.650.2169-112.14----2.61-193.47---5,240.000.00--35.25-48.7269.97------
Kyntra Bio Inc8.30m-131.13m27.67m225.00------3.33-32.4953.342.05-4.210.0413-1.470.42136,880.00-64.00-39.47-260.98-61.33345.6990.21-1,548.18-199.023.60--0.5269---36.71-35.0752.60---45.94--
Aytu Biopharma Inc62.64m-24.56m28.34m82.00--2.00--0.4524-3.40-3.395.631.320.52592.102.22763,902.40-20.62-26.47-45.22-47.3266.8460.56-39.21-52.541.030.0570.5958--1.8419.16-13.27------
United-Guardian Inc10.06m1.96m30.28m24.0015.452.8614.673.010.42660.42662.192.300.79113.827.58419,180.4015.4126.9117.8531.1650.6054.1619.4826.976.16--0.0092.3411.91-2.1825.94-7.3530.65-8.64
SCYNEXIS Inc2.93m-25.30m31.55m28.00--0.8659--10.76-0.5107-0.51070.05930.86830.0391--0.5776104,714.30-33.71-20.51-43.65-24.9733.32---862.89-64.82----0.00---97.3398.68-131.75------
Earth Science Tech Inc34.87m3.51m32.05m76.009.435.608.280.91910.01170.01170.11580.01965.0614.89148.30458,876.6050.5224.0476.21--73.8471.089.995.500.86065.650.0067--177.05128.98300.63------
Celularity Inc40.58m-80.71m33.45m123.00------0.8244-3.34-3.341.69-0.71210.33396.145.24329,902.40-66.35-23.42-158.76-26.8350.61---198.75-294.700.123-6.572.01--138.11--70.51------
BioXcel Therapeutics Inc752.00k-68.21m34.99m37.00------46.53-10.41-10.410.1023-4.450.0160.9718501.3320,324.32-145.62-76.45-449.90-88.28-28.19---9,070.61-14,760.231.16-3.255.40--64.20--66.71------
Rockwell Medical Inc75.58m-5.48m35.44m244.00--0.9574--0.4689-0.1583-0.15832.200.93951.3212.928.78309,741.80-9.63-32.92-12.15-46.6115.818.00-7.30-23.863.50-6.130.2141--21.3810.6194.31--11.47--
Zhengye Biotechnology Holding Ltd22.28m-2.81m36.49m277.00--0.8423107.871.64-0.0591-0.05910.47930.91420.30991.622.0480,439.45-4.60---7.79--37.37---14.83--1.10-7.000.1902---11.95---64.04------
Medicus Pharma Ltd-100.00bn-100.00bn36.92m-----------------0.0434-----------361.95----------------1.13-------109.90------
NovaBay Pharmaceuticals Inc2.83m-7.95m38.66m14.00------13.66-7.912.692.771.360.7686--5.28202,142.90-215.92-61.58-404.37-83.7954.5659.49-280.92-77.39---91.560.0836---33.588.1948.52---20.59--
Healthy Extracts Inc3.59m-1.17m39.65m2.00--1.65--11.05-0.3195-0.31950.90951.430.25051.42140.671,794,555.00-8.19-61.21-9.09-111.6052.3751.30-32.71-82.010.6491-2.840.0421--25.2432.9966.01------
Talphera Inc28.00k-12.46m41.73m13.00--2.13--1,490.51-0.3808-0.3780.00090.42070.0011----2,153.85-48.15-14.86-54.44-19.40-----44,503.57-446.19----0.00---100.00---26.41------
BioScience Health Innovations Inc4.73m885.68k43.92m--206.5025.67--9.290.01940.01940.13130.15583.814.3099.37--71.34--85.11--63.64--18.74--3.47--0.00--208.73--134.59------
Telomir Pharmaceuticals Inc0.00-11.25m44.87m----6.33-----0.3739-0.37390.000.20630.00-------266.47---303.19--------------0.00-------26.48------
Data as of Mar 04 2026. Currency figures normalised to Zhengye Biotechnology Holding Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.49%Per cent of shares held by top holders
HolderShares% Held
Winton Capital Management Ltd.as of 31 Dec 202563.30k0.13%
XTX Markets LLCas of 31 Dec 202559.29k0.13%
Invesco Capital Management LLCas of 31 Dec 202534.69k0.07%
Citadel Securities LLCas of 31 Dec 202530.58k0.07%
Geode Capital Management LLCas of 31 Dec 202529.07k0.06%
UBS Securities LLCas of 31 Dec 20259.12k0.02%
Tower Research Capital LLCas of 31 Dec 20252.21k0.01%
Morgan Stanley & Co. LLCas of 31 Dec 20251.61k0.00%
JPMorgan Securities LLC (Investment Management)as of 31 Dec 2025457.000.00%
RBC Capital Markets LLC (Investment Management)as of 31 Dec 2025383.000.00%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.